Orion Corporation share buyback programme 2026
Analysis based on 7 articles · First reported Sep 04, 2026 · Last updated Sep 18, 2026
The buyback programme provides modest support to Orion's share price by reducing the number of shares outstanding and signaling management confidence in the company's valuation. The impact on broader markets is minimal, as this is a routine, pre-announced corporate action by a mid-cap Nordic pharmaceutical company.
Orion is executing a share buyback programme announced on 27 August 2026, running from 1 September 2026 until no later than 31 December 2026. The buybacks are executed in compliance with Regulation No. 596/2014 (MAR) Article 5 and Commission Delegated Regulation (EU) 2016/1052. During week 36 of 2026, Orion acquired 102,722 Class B shares (trading code ORNBV) on the exchange at an average price of EUR 80.1814 per share, for a total transaction value of EUR 8,236,395.60. During week 37 of 2026, it acquired 138,084 shares at an average price of EUR 79.5987, totaling EUR 10,991,306.89. During week 38 of 2026, it acquired 107,674 shares at an average price of EUR 80.4870, totaling EUR 8,666,359.16. After these acquisitions, Orion holds a total of 616,646 treasury shares, all of which are Class B shares. The buybacks are carried out on behalf of Orion by Danske Bank A/S, Finland Branch, with Antti Valiaho and Jonathan Nyberg named as representatives. Orion Pharma is a globally operating Nordic pharmaceutical company with 2025 net sales of EUR 1,890 million and about 4,000 employees worldwide.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard